Emergent BioSolutions Inc. (NYSE: EBS)

Emergent BioSolutions Inc. (EBS), a globally recognized life sciences company, specializes in providing innovative solutions that address accidental, deliberate, and naturally occurring public health threats. Its primary business activities encompass the development, manufacturing, and commercialization of a wide range of medical countermeasures (MCMs) and the provision of bioservices. EBS operates in various countries, including the United States, Canada, and Europe.

The company generates revenue through the sale of its MCMs, bioservices, and non-dilutive contract and grant funding for research and development (R&D) projects. EBS's product portfolio includes NARCAN(R) Nasal Spray, ACAM2000(R) (Smallpox Vaccine, Live), ANTHRASIL(R) (Anthrax Immune Globulin Intravenous (human)), BAT(R) [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) ; (Equine)], BioThrax(R) (Anthrax Vaccine Adsorbed), CYFENDUS(R) (Anthrax Vaccine Adsorbed, Adjuvanted), Ebanga(R) (ansuvimab-zykl), Raxibacumab injection, RSDL(R) (Reactive Skin Decontamination Lotion Kit), TEMBEXA(R) (brincidofovir), and VIGIV CNJ-016(R) (Vaccinia Immune Globulin Intravenous (Human)). These products cater to government agencies, including the USG, and have been procured for emergency preparedness purposes.

EBS maintains a strong position within the industry due to its diverse portfolio of MCMs and bioservices. Its products are used by government agencies and other organizations involved in public health preparedness and response. The company's competitors include Lonza Group Ltd., Catalent, Inc., Thermo Fisher Scientific, Curia Global, Inc., Resilience, Grand River Aseptic Manufacturing, Berkshire Sterile Manufacturing, Jubilant HollisterSteirVetter Pharma, and FUJIFILM Diosynth Biotechnologies. EBS's competitive advantages include its established development and manufacturing infrastructure, technology platforms, and expertise.

The primary customers for EBS's products include government agencies, particularly the USG, as well as other organizations involved in public health preparedness and response. The company's bioservices cater to innovators in the biotechnology and pharmaceutical segments.

The following is a list of the brand names and/or trade names of the company's products and services:

1. NARCAN(R) Nasal Spray
2. ACAM2000(R) (Smallpox Vaccine, Live)
3. ANTHRASIL(R) (Anthrax Immune Globulin Intravenous (human))
4. BAT(R) [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) ; (Equine)]
5. BioThrax(R) (Anthrax Vaccine Adsorbed)
6. CYFENDUS(R) (Anthrax Vaccine Adsorbed, Adjuvanted)
7. Ebanga(R) (ansuvimab-zykl)
8. Raxibacumab injection
9. RSDL(R) (Reactive Skin Decontamination Lotion Kit)
10. TEMBEXA(R) (brincidofovir)
11. VIGIV CNJ-016(R) (Vaccinia Immune Globulin Intravenous (Human))

EBS's manufacturing operations are based on an internal and external network of manufacturers and other third parties. The company relies on single-source suppliers for certain raw materials and supplies, including Alhydrogel(R) adjuvant 2% used to manufacture CYFENDUS(R) and BioThrax(R) vaccines.